Register
Login:
Share:
Email Facebook Twitter

Early Stage Investment Opportunities: SyndicateRoom, investing from idea to IPO. Watch here

Share Views Episode 9 - Early Stage Investment Opportunities


Sareum Share Chat (SAR)



Share Price: 0.615Bid: 0.58Ask: 0.65Change: -0.01 (-1.60%)Faller - Sareum
Spread: 0.07Spread as %: 12.07%Open: 0.60High: 0.00Low: 0.00Yesterday’s Close: 0.625


Share Discussion for Sareum


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


Utahsaints
Posts: 723
Off Topic
Opinion:No Opinion
Price:0.615
RE: BOD news suppression . . .
Today 07:54
500m and I would make 400k which would be very nice but I just think we are moving down for a while without news
 
potnak
Posts: 275
Off Topic
Opinion:No Opinion
Price:0.615
RE: BOD news suppression . . .
Today 07:51
Jon

I wouldn't scoff at that, it isn't strange at all. £500m for similar compounds is probably in the mid range of dealsl, they could be worth more but to get more, I believe we'd have to take it into phase II ourselves.
potnak
Posts: 275
Off Topic
Opinion:No Opinion
Price:0.625
RE: Disclosure
Today 07:44
I still believe this all adds up to the fact that his hands are tied because of ongoing discussions.. They know we are going to find this stuff anyway and this way the herd doesn't come along to mess everything up.
Thoth2
Posts: 936
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.625
View Thread (2)
RE: Disclosure
Mon 23:39
TIM said news in q2/q3con aurora and on tyk 2.

If it's not newsworthy he should not have flagged it in may as not newsworthy.

He flagged the newsflow. We know tyk 2 has filed it's reports with innovate UK. We know subsequent studies have started with 3rd parties. So what the complete contempt for shareholders. Promising news. And then giving it to other sources but not your shareholders.
Why flag the potential newsflow in may and thenot withhold.
It's not unrealistic expectations. It is expectations that the bod set themselves publicly that they have failed to deliver on. Where is the tyk2 innovate UK funded research that delivered in August?
Thoth2
Posts: 936
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.625
Disclosure
Mon 21:41
The line is.. 85% of takeovers in the US are subject to lawsuits for conflict of interest of directors. Mostly the directors are keener to ensure continuing employment and do a deal in detriment to other shareholders. The website has been cleaned up this week. We had the Berlin listing last week. Being wise in foresight better than in hindsight. My money is in AZN for chk1 (poss with lilly). And j&J for the rest of the company including skil.
JonTangle
Posts: 151
Off Topic
Opinion:No Opinion
Price:0.625
RE: BOD news suppression . . .
Mon 21:22
I know a lot may scoff at a 4/500m buyout but stranger things have happened, albeit there is little incentive to go in with a high offer other than the hopeful avoidance of a bidding war?

For those thinking who can afford it etc, granted a totally different field but I would use the case of BP for how monster corporations fund things. Their Macondo oil well disaster resulted in an $18.7 billion fine spread over 18 years. That's $3 million a day and yet the dividend wasn't touched. That's the sort of buying power for corporations of that size. Chicken feed to your GSKs or your AZNs. Chicken feed.
Thoth2
Posts: 936
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.625
RE: BOD news suppression . . .
Mon 19:31
I have an alternative view that takeover discussions have been underway since Parker was appointed. So planned news hasn't been released. It may not materialise as it didn't in 2011. But we will know soon enough. Gla
Arbitrage
Posts: 919
Observation
Opinion:No Opinion
Price:0.625
BOD news suppression . . .
Mon 19:12
is clearly and imo, intentionally evident here:

Firstly, it was the failure of the BOD to appropriately and timeously release an appropriately worded rns informing both 'The Market', along with the company's shareholders of the below compound back in 2013 which, when the info was eventually recently 'teased out of the BOD' confirmed the beneficial effect of the compound CCT244747 in respect of the treatment of BOTH head and neck cancers, when combined with radiotherapy:

http://www.investegate.co.uk/sareum-holdings-plc--sar-/rns/movement-in-share-price/201607280700104505F/

Secondly, as kindly highlighted in his 16:11 post of this afternoon by Thoth2, info has now been 'sneaked' onto the Sareum website as outlined below:

http://genomebiology.biomedcentral.com/articles/10.1186/s13059-016-1042-9

In conclusion, the above info only serves to confirm my own personal suspicions that, 'Timbo' has and indeed, continues to play 'fast and loose' with the company's corporate news-flow and by default, the company's corresponding sp/market cap. In so doing, said actions have, I firmly believe, served to keep SAR under the radar and associated scrutiny of Institutional Investors and in so doing has enabled the BOD of SAR, for far too long, to run this organisation as their "personal fiefdom."

However, whilst the above ruminations along with several other concerns which I harbor in respect of the running of SAR by the current management may, or may not, prove to be correct, I have every faith in the ability of the FCA in determining that fact and to that end, I await the outcome of their evaluation in due course!
Thoth2
Posts: 936
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.625
new research
Mon 16:11
This has actually sneaked onto the sareum website under "research & publications". published 15th September
http://genomebiology.biomedcentral.com/articles/10.1186/s13059-016-1042-9

our Chk1 inhibitor if you look hard enough.......
Searle
Posts: 54
Observation
Opinion:No Opinion
Price:0.655
Price of the drug
Mon 13:51
Interesting link. £504 for a 10mg tablet. And that's not a retail price. A course of Sarumzumab might cost thousands...




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.